A new trading day began on Friday, with Karyopharm Therapeutics Inc (NASDAQ: KPTI) stock price down -9.00% from the previous day of trading, before settling in for the closing price of $5.0. KPTI’s price has ranged from $3.51 to $16.95 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 27.91% over the last five years. Meanwhile, its annual earnings per share averaged 10.98%. With a float of $7.96 million, this company’s outstanding shares have now reached $8.57 million.
The firm has a total of 279 workers. Let’s measure their productivity. In terms of profitability, gross margin is 96.14%, operating margin of -83.69%, and the pretax margin is -43.98%.
Karyopharm Therapeutics Inc (KPTI) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Karyopharm Therapeutics Inc is 7.84%, while institutional ownership is 50.13%. The most recent insider transaction that took place on May 06 ’25, was worth 1,680. In this transaction President and CEO of this company sold 236 shares at a rate of $7.12, taking the stock ownership to the 82,503 shares. Before that another transaction happened on Apr 23 ’25, when Company’s EVP & Chief Medical Officer sold 419 for $6.17, making the entire transaction worth $2,585. This insider now owns 28,853 shares in total.
Karyopharm Therapeutics Inc (KPTI) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -2.96 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 10.98% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 47.98% during the next five years compared to 27.91% growth over the previous five years of trading.
Karyopharm Therapeutics Inc (NASDAQ: KPTI) Trading Performance Indicators
Here are Karyopharm Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.28. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.28.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -13.26, a number that is poised to hit -4.08 in the next quarter and is forecasted to reach -7.66 in one year’s time.
Technical Analysis of Karyopharm Therapeutics Inc (KPTI)
Analysing the last 5-days average volume posted by the [Karyopharm Therapeutics Inc, KPTI], we can find that recorded value of 0.42 million was better than the volume posted last year of 0.11 million. As of the previous 9 days, the stock’s Stochastic %D was 79.09%.
During the past 100 days, Karyopharm Therapeutics Inc’s (KPTI) raw stochastic average was set at 15.14%, which indicates a significant decrease from 59.11% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.40 in the past 14 days, which was lower than the 0.58 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.91, while its 200-day Moving Average is $8.46. Now, the first resistance to watch is $4.85. This is followed by the second major resistance level at $5.16. The third major resistance level sits at $5.74. If the price goes on to break the first support level at $3.97, it is likely to go to the next support level at $3.39. Now, if the price goes above the second support level, the third support stands at $3.09.
Karyopharm Therapeutics Inc (NASDAQ: KPTI) Key Stats
With a market capitalization of 39.31 million, the company has a total of 8,640K Shares Outstanding. Currently, annual sales are 145,240 K while annual income is -76,420 K. The company’s previous quarter sales were 30,020 K while its latest quarter income was -23,460 K.
